KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

CRISPR Therapeutics AG (CRSP) Return on Sales (2016 - 2025)

CRISPR Therapeutics AG's Return on Sales history spans 11 years, with the latest figure at 150.11% for Q4 2025.

  • For Q4 2025, Return on Sales fell 16037.0% year-over-year to 150.11%; the TTM value through Dec 2025 reached 165.44%, down 16643.0%, while the annual FY2025 figure was 165.44%, 16643.0% down from the prior year.
  • Return on Sales for Q4 2025 was 150.11% at CRISPR Therapeutics AG, down from 119.73% in the prior quarter.
  • Across five years, Return on Sales topped out at 10.26% in Q4 2024 and bottomed at 18809.5% in Q4 2022.
  • The 5-year median for Return on Sales is 152.21% (2021), against an average of 1183.94%.
  • The largest annual shift saw Return on Sales plummeted -1879868bps in 2022 before it soared 1881084bps in 2023.
  • A 5-year view of Return on Sales shows it stood at 10.82% in 2021, then crashed by -173795bps to 18809.5% in 2022, then soared by 100bps to 1.34% in 2023, then soared by 664bps to 10.26% in 2024, then plummeted by -1563bps to 150.11% in 2025.
  • Per Business Quant, the three most recent readings for CRSP's Return on Sales are 150.11% (Q4 2025), 119.73% (Q3 2025), and 233.81% (Q2 2025).